Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial - Aix-Marseille Université Access content directly
Journal Articles Lancet Oncology Year : 2010

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

Domains

Cancer

Dates and versions

hal-03623804 , version 1 (29-03-2022)

Identifiers

Cite

Axel Le Cesne, Isabelle Ray-Coquard, Binh Nguyen Bui, Antoine Adenis, Maria Rios, et al.. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncology, 2010, 11 (10), pp.942-949. ⟨10.1016/s1470-2045(10)70222-9⟩. ⟨hal-03623804⟩
16 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More